 Jennifer Soep
Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 6 | 2013 | 250 | 0.560 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 678 | 0.390 |
Why?
| | Education, Medical, Undergraduate | 5 | 2022 | 177 | 0.370 |
Why?
| | Vasculitis | 2 | 2021 | 60 | 0.290 |
Why?
| | Drug Hypersensitivity Syndrome | 1 | 2024 | 1 | 0.230 |
Why?
| | Arteriosclerosis | 1 | 2004 | 88 | 0.220 |
Why?
| | Clinical Competence | 3 | 2020 | 1021 | 0.210 |
Why?
| | Atherosclerosis | 3 | 2013 | 410 | 0.200 |
Why?
| | Heptanoic Acids | 2 | 2013 | 62 | 0.200 |
Why?
| | Osteomyelitis | 1 | 2024 | 124 | 0.200 |
Why?
| | Antirheumatic Agents | 2 | 2018 | 282 | 0.190 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 28 | 0.190 |
Why?
| | Pyrroles | 2 | 2013 | 192 | 0.180 |
Why?
| | Interleukin-6 | 1 | 2024 | 718 | 0.170 |
Why?
| | Interleukin-1 | 1 | 2024 | 961 | 0.170 |
Why?
| | Internship and Residency | 2 | 2020 | 1061 | 0.160 |
Why?
| | Models, Psychological | 1 | 2020 | 307 | 0.150 |
Why?
| | Infliximab | 1 | 2018 | 100 | 0.150 |
Why?
| | Pediatrics | 2 | 2018 | 1062 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 872 | 0.140 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2018 | 130 | 0.140 |
Why?
| | Child | 14 | 2024 | 20805 | 0.140 |
Why?
| | Competency-Based Education | 1 | 2018 | 70 | 0.140 |
Why?
| | Narration | 1 | 2017 | 56 | 0.140 |
Why?
| | Learning | 2 | 2018 | 396 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2018 | 236 | 0.130 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1417 | 0.130 |
Why?
| | C-Reactive Protein | 3 | 2013 | 397 | 0.120 |
Why?
| | Echocardiography | 1 | 2018 | 627 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 343 | 0.120 |
Why?
| | Aspirin | 1 | 2018 | 378 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 82 | 0.120 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2014 | 89 | 0.110 |
Why?
| | Students, Medical | 2 | 2017 | 318 | 0.110 |
Why?
| | Skin | 1 | 2018 | 719 | 0.110 |
Why?
| | Capillaries | 1 | 2013 | 92 | 0.110 |
Why?
| | Adolescent | 13 | 2024 | 20301 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 44 | 0.100 |
Why?
| | Twins, Monozygotic | 1 | 2013 | 209 | 0.100 |
Why?
| | Biomarkers | 4 | 2013 | 3896 | 0.100 |
Why?
| | Male | 16 | 2024 | 63201 | 0.100 |
Why?
| | Lupus Nephritis | 1 | 2012 | 56 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Remission Induction | 1 | 2012 | 271 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 162 | 0.090 |
Why?
| | Pulmonary Alveoli | 1 | 2013 | 366 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 144 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 249 | 0.090 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 81 | 0.090 |
Why?
| | Humans | 22 | 2024 | 129126 | 0.080 |
Why?
| | Anticholesteremic Agents | 1 | 2012 | 146 | 0.080 |
Why?
| | Lung Diseases | 2 | 2013 | 723 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| | Hemorrhage | 1 | 2013 | 645 | 0.080 |
Why?
| | Carotid Artery, Common | 1 | 2009 | 37 | 0.080 |
Why?
| | Tunica Intima | 1 | 2009 | 82 | 0.080 |
Why?
| | Arthritis, Juvenile | 1 | 2009 | 54 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 413 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2010 | 126 | 0.080 |
Why?
| | Venous Thromboembolism | 1 | 2012 | 275 | 0.070 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 250 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 690 | 0.070 |
Why?
| | Cholesterol, LDL | 2 | 2013 | 361 | 0.070 |
Why?
| | Age of Onset | 2 | 2009 | 494 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1098 | 0.070 |
Why?
| | Female | 15 | 2024 | 68517 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2009 | 306 | 0.070 |
Why?
| | Child, Preschool | 5 | 2024 | 10450 | 0.060 |
Why?
| | Education, Medical, Graduate | 2 | 2022 | 439 | 0.060 |
Why?
| | Chilblains | 1 | 2005 | 3 | 0.060 |
Why?
| | Apolipoprotein A-I | 1 | 2004 | 28 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 84 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1067 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2024 | 49 | 0.060 |
Why?
| | Risk Factors | 5 | 2012 | 9768 | 0.050 |
Why?
| | Curriculum | 2 | 2022 | 925 | 0.050 |
Why?
| | Cholesterol, HDL | 1 | 2004 | 203 | 0.050 |
Why?
| | Double-Blind Method | 3 | 2013 | 1865 | 0.050 |
Why?
| | Faculty, Medical | 2 | 2017 | 266 | 0.050 |
Why?
| | Spine | 1 | 2024 | 159 | 0.050 |
Why?
| | Infant | 4 | 2024 | 8992 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2013 | 91 | 0.050 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 20 | 0.050 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 33 | 0.050 |
Why?
| | Delphi Technique | 1 | 2022 | 226 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2004 | 846 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 371 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1741 | 0.040 |
Why?
| | Cytokines | 2 | 2021 | 1987 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 638 | 0.040 |
Why?
| | Prospective Studies | 4 | 2013 | 7079 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2668 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 2024 | 0.040 |
Why?
| | Prevalence | 1 | 2024 | 2564 | 0.040 |
Why?
| | Treatment Outcome | 4 | 2013 | 10226 | 0.030 |
Why?
| | Schools, Medical | 1 | 2018 | 131 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2004 | 3342 | 0.030 |
Why?
| | Colorado | 3 | 2012 | 4396 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 701 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 6518 | 0.030 |
Why?
| | Disease Progression | 2 | 2013 | 2613 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2024 | 14571 | 0.030 |
Why?
| | Young Adult | 4 | 2012 | 12389 | 0.030 |
Why?
| | Prognosis | 2 | 2012 | 3788 | 0.030 |
Why?
| | Polysaccharides | 1 | 2012 | 81 | 0.020 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 32 | 0.020 |
Why?
| | Puberty | 1 | 2013 | 143 | 0.020 |
Why?
| | Focus Groups | 1 | 2014 | 455 | 0.020 |
Why?
| | Enoxaparin | 1 | 2012 | 59 | 0.020 |
Why?
| | Immunomodulation | 1 | 2012 | 89 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 301 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2013 | 207 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2011 | 4915 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2011 | 66 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 337 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 163 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 3700 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 183 | 0.020 |
Why?
| | Lipoproteins, HDL | 1 | 2010 | 85 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 110 | 0.020 |
Why?
| | Placebos | 1 | 2010 | 201 | 0.020 |
Why?
| | Lipoprotein(a) | 1 | 2010 | 67 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 56 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1003 | 0.020 |
Why?
| | Montana | 1 | 2009 | 18 | 0.020 |
Why?
| | Blood Sedimentation | 1 | 2009 | 34 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 229 | 0.020 |
Why?
| | Utah | 1 | 2009 | 65 | 0.020 |
Why?
| | Azathioprine | 1 | 2009 | 49 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2009 | 83 | 0.020 |
Why?
| | Cholesterol | 1 | 2010 | 406 | 0.020 |
Why?
| | Receptors, Interleukin-1 | 1 | 2009 | 223 | 0.020 |
Why?
| | Lipoproteins | 1 | 2009 | 171 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 236 | 0.020 |
Why?
| | Triglycerides | 1 | 2010 | 524 | 0.020 |
Why?
| | Lipids | 1 | 2012 | 624 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 614 | 0.020 |
Why?
| | Qualitative Research | 1 | 2014 | 1231 | 0.020 |
Why?
| | Creatinine | 1 | 2009 | 475 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2009 | 519 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 3120 | 0.020 |
Why?
| | Ultrasonography | 1 | 2009 | 724 | 0.020 |
Why?
| | Adult | 2 | 2005 | 35512 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1945 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1465 | 0.010 |
Why?
| | Sex Factors | 1 | 2009 | 1953 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2635 | 0.010 |
Why?
| | Acute Disease | 1 | 2005 | 968 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5407 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2541 | 0.010 |
Why?
| | United States | 1 | 2018 | 13939 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2266 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5070 | 0.010 |
Why?
|
|
Soep's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|